What Smofkabiven Treats: Main Uses and Benefits

SmofKabiven is used for patients—adults and children aged two years and above—who require Total Parenteral Nutrition (TPN) because their medical condition prevents them from receiving adequate nutrition through the digestive system. This essential supportive therapy is indicated for patients when oral or enteral nutrition is impossible, insufficient or contraindicated.

This complete nutritional support is commonly used in conditions that result in severe malabsorption, significant vomiting, and muscle wasting. It is relevant for managing moderate to severe malnutrition and easing the symptoms of catabolic stress in clinical scenarios such as: major surgery, critical illness, and chronic conditions like permanent intestinal failure. “This supportive therapy helps to address the systemic consequences of severe malabsorption or intractable vomiting and diarrhea.”

The therapy generally contributes to maintaining energy reserves and may assist patients with functional stability for extended periods, including use in home care settings.

---

Quick Fact: Supportive Role in Severe Nutritional Deficits

Condition Category	Symptom Domain Addressed	Patient Benefit
Gastrointestinal Failure	Inability to absorb/tolerate food	Provides complete nutritional sustenance
Catabolic Stress	Muscle wasting, severe weight loss	Helps halt tissue breakdown
Chronic Intestinal Conditions	Need for long-term sustenance	Supports continuous functional stability

Regulatory References

1. TGA Public Assessment Report for SmofKabiven

Smofkabiven is officially approved for use in adults and children aged two years and above who require total parenteral nutrition. Its eligibility profile is strictly defined by regulatory guidelines based on the patient's existing health status and age.

Contraindications (Must Not Use)

The medicine is strictly contraindicated for several patient groups. Individuals with known hypersensitivity to fish, egg, soybean, or peanut protein must not use the medicine. Absolute contraindications also include conditions of severe, uncompensated organ or metabolic failure, such as severe hyperlipidemia, severe liver insufficiency, or severe renal insufficiency without dialysis. Use is also prohibited in patients with congenital errors of amino acid metabolism, those in acute shock, or those experiencing uncontrolled hyperglycemia or other acute, unstable clinical conditions.

Age and Restricted Use

Smofkabiven is not recommended for infants and newborns under two years of age because its fixed composition does not meet their specialized nutritional needs. Use in patients with certain comorbidities, such as renal failure or diabetes mellitus, is conditional and requires enhanced caution and close monitoring. Regulatory data on its use during pregnancy and breastfeeding is lacking, and its administration is conditional upon necessity determined by the prescribing physician.

Interactions with other medicines and products

The official interaction profile for Smofkabiven, a complex parenteral nutrition emulsion, is defined by substances that affect the clearance of its lipid component and by specific procedural requirements related to administration.

Medicines Affecting Lipid Metabolism

Some medicinal products are officially documented as potentially affecting the clearance of the emulsion’s fat component from the bloodstream. Co-administration with Heparin, for example, causes a transient release of lipoprotein lipase into the circulation. This results in an initial increase in plasma lipolysis, which is followed by a transient decrease in the overall clearance of triglycerides. Separately, drugs such as Insulin may also interfere with the body's lipase system. However, the official regulatory description of the interaction with Insulin qualifies this effect as being of limited clinical importance.

Procedural Constraints and Incompatibilities

Specific rules govern the simultaneous administration of this infusion with other products. Smofkabiven must not be simultaneously administered with whole blood or packed red blood cells through the same intravenous line due to the pharmaceutical risk of pseudoagglutination, or clumping. Furthermore, the high fat content of the emulsion may officially interfere with certain laboratory measurements (including tests for hemoglobin and bilirubin). To prevent interference with diagnostic results, blood sampling for these measurements must be delayed until the fat component has been adequately cleared from the bloodstream. The regulatory labels do not list any specific drug-drug combinations as formal contraindications based on interaction risk.

Smofkabiven is a compound nutrient admixture intended for systemic delivery via the vasculature, targeting cellular metabolism throughout the body. Its mechanistic action involves the simultaneous provision of amino acids, glucose, lipids, electrolytes, and micronutrients, serving as fundamental substrates for multiple metabolic and synthetic pathways.

The amino acid component facilitates protein synthesis by entering the intracellular space via specific amino acid transporters, becoming direct precursors for ribosomal polypeptide elongation. Glucose enters cells through GLUT transporters and is immediately phosphorylated by hexokinase to enter glycolysis, generating pyruvate for entry into the Krebs cycle and subsequent oxidative phosphorylation, producing adenosine triphosphate (ATP).

The lipid emulsion, containing triglycerides, is hydrolyzed by lipoprotein lipase at the capillary endothelium into free fatty acids and glycerol. Free fatty acids are transported into the mitochondria via the carnitine shuttle for beta-oxidation, yielding acetyl-CoA, which also fuels the Krebs cycle.

Downstream, the sustained supply of these substrates modulates key anabolic and catabolic signaling, maintaining cellular energy charge and supporting the structural integrity and functional output of systemic organ systems, including the preservation of lean body mass and sustained visceromotor activity.

Instruction Map: How to use Smofkabiven — Official Administration Guidelines

Smofkabiven is an emulsion for intravenous infusion and must be administered under the direction of a healthcare professional. Dosing is highly individualized based on the patient's body weight, clinical status, and specific nutritional requirements, including any concurrent oral or enteral intake.

Administration Scope

Classification	Rule
Route of Administration	Intravenous infusion. Must be administered into a central vein (or peripheral vein for low-osmolality formulations, like Smofkabiven Peripheral).
Official Dosing	Daily dose and infusion rate are determined by the physician. The dosage range for adults is typically 13 - 40 mL/ kg body weight per day.
Infusion Timing/Frequency	Continuous infusion, typically administered over a period of 14 - 24 hours daily. The maximum infusion rate must not be exceeded.
Age-Group Rules	Adults and Adolescents (12 years): Use standard adult dosing. Children (2-11 years): Dosing requires individual adjustment and careful monitoring. Children < 2 years are not recommended for use.

Preparation and Procedural Steps

1. Preparation: The three-chamber bag must be mixed prior to use. Remove the protective overpouch and oxygen absorber. Place the bag on a flat surface and roll it tightly to break the vertical seals separating the chambers (amino acids, glucose, and lipids). The contents must be gently mixed by inverting the bag a few times until the emulsion is homogeneous and white.
2. Additives: Electrolytes, vitamins, or trace elements may be added via the dedicated additive port after the three chambers have been mixed, using strict aseptic technique.
3. Administration: The mixture should be at room temperature (15°C to 25°C) before infusing. It must be administered using a dedicated intravenous line and a continuous, controlled infusion device, typically with a 1.2 micron in-line filter. Any unused solution remaining after the infusion should be discarded. The infusion must be stopped immediately if signs of an allergic reaction occur.

Research Evidence: Overview of Studies for Smofkabiven

Evidence for Use in Total Nutritional Support for Adults

The research conducted for this medicine includes short-term, randomized controlled trials (RCTs). These studies were active-controlled, comparing the product directly against other standard intravenous nutrition (IV) solutions used in hospitals. Research was used in settings where adult patients required total nutritional support because they could not receive adequate food through the digestive system.

Research was designed to examine the nutritional biomarker equivalence between the treatments. The main outcome monitored was the change in serum prealbumin levels—a protein biomarker that helps gauge nutritional status over a short period. Studies monitored measurements where changes in prealbumin were observed during the study period for both the product and comparator solutions.

The Role of the Unique Four-Oil Lipid Component in Research

This product includes a four-oil lipid emulsion, which includes refined soya bean, medium-chain triglycerides, olive oil, and fish oil. Specialized network meta-analyses and systematic reviews research examined how this blend compared to simpler lipid components that have traditionally been used in IV nutrition.

These aggregated research summaries explored clinical measures related to patient recovery, such as the risk of developing hospital-acquired infections and the length of time patients spent in the hospital. Findings observed in these studies indicated mixed or heterogeneous patterns across the reviewed trials. Research explored potential differences in outcomes related to this specific lipid formulation, and the certainty of these findings remains low due to variations in the data.

Duration of Study and Key Gaps

The core short-term, comparative studies research examined changes in nutritional biomarkers over a very short period, typically less than one week. Follow-up durations were limited in these key comparative trials. Research so far provides insight into short-term changes, and long-term effects are not fully established based on these primary studies.

A significant part of the primary evidence relies on surrogate endpoints like serum prealbumin, which are lab values, not measures of definitive patient outcomes like enhanced functional recovery. The absence of dedicated clinical trials using the fixed-combination product in the youngest approved pediatric age groups suggests that subgroup findings remain uncertain.

Common questions about Smofkabiven (FAQ)

Q: Is Smofkabiven the same as TPN (Total Parenteral Nutrition)?

A: Smofkabiven is officially classified as a solution for Parenteral Nutrition (PN). It provides all necessary components for complete nourishment via the bloodstream. TPN, which stands for Total Parenteral Nutrition, is a common clinical term used in healthcare to describe this type of comprehensive nutritional support.

Q: Why do doctors use Smofkabiven instead of just a regular IV?

A: Smofkabiven is a specialized product designed to provide total nutritional support when a patient cannot get enough nutrients through the digestive system. It is a complete mixture that contains amino acids, glucose, lipids, and electrolytes. In contrast, a regular IV solution, such as simple saline, does not provide this complete range of necessary nutritional components.

Q: Is it normal to feel tired or weak when first starting Smofkabiven?

A: The official product safety documents list common infusion-related effects such as nausea, vomiting, and fever (pyrexia). The documents do not specifically list fatigue or weakness as documented common side effects. Official documents suggest patients should inform their healthcare professional if they experience any unexpected signs during the infusion.

Q: How long can a person expect to be on Smofkabiven?

A: The duration of use is determined by a healthcare professional and is highly individualized based on a patient's nutritional requirements and clinical condition. Official information indicates that the treatment duration for Smofkabiven in the populations studied should typically not exceed 30 days.

Q: Are there different versions or formulas of Smofkabiven? (e.g., Central vs. Peripheral)

A: Yes, regulatory documents confirm that Smofkabiven is available in different formulations. The standard product is generally intended for infusion into a large vein (central line). A separate version, Smofkabiven Peripheral, has a lower concentration and may be given through a smaller, peripheral vein.

Q: Does Smofkabiven affect blood sugar levels?

A: Since the product contains glucose (a type of sugar), regulatory documents require that blood sugar levels (serum glucose) must be carefully monitored during treatment. Official guidance indicates that uncontrolled high blood sugar (hyperglycemia) is a condition that contraindicates the use of the product.

Q: What is the difference between Smofkabiven and other 'kabiven' products?

A: The key distinguishing feature described in official documents is the lipid (fat) component. Smofkabiven contains a unique four-oil lipid emulsion (SMOF), which is a blend of refined soya bean oil, medium-chain triglycerides, refined olive oil, and fish oil. Other products in the Kabiven family may feature different lipid blends.

Q: Can Smofkabiven be given through a regular peripheral IV, or does it need a central line?

A: The standard formulation of Smofkabiven must be administered through a central vein due to its concentration. However, official sources indicate that a separate formulation, Smofkabiven Peripheral, has a lower concentration that allows it to be infused into either a peripheral vein or a central vein.

Q: Do you have to take other medications when you are on Smofkabiven?

A: According to official guidance, additional trace elements, vitamins, and electrolytes are typically needed to ensure the patient's nutritional requirements are fully met. These components should be added to the bag according to the patient’s individual needs.

Q: Can Smofkabiven be stopped suddenly, or does it require tapering?

A: The official patient information indicates that the infusion should not be discontinued without consultation with a healthcare professional. The only exception is if a patient shows signs of an allergic reaction, in which case the infusion must be stopped immediately.

Q: Does alcohol use interact with Smofkabiven?

A: Regulatory documents indicate that the effects of alcohol on the body while receiving Smofkabiven infusion have not been specifically studied by the manufacturer. A healthcare professional is best suited to provide guidance on this matter.

Q: Can people who are lactose intolerant or have celiac disease use Smofkabiven?

A: Official product information confirms that one formulation of Smofkabiven does not contain gluten or lactose. However, the product is not to be used if a patient has a known hypersensitivity or allergy to components such as fish, egg, soybean, or peanut protein.

Q: Does Smofkabiven affect the ability to drive or operate machinery?

A: The official documentation notes that studies to evaluate the effect of Smofkabiven on driving and operating machinery were not conducted. This is primarily because the medicine is typically administered to patients in a controlled hospital or clinical setting.

Q: Does Smofkabiven cause weight gain?

A: As a complete nutritional product, Smofkabiven provides all the energy and building blocks (calories and protein) needed to reverse malnutrition and maintain a healthy body weight. Any changes in weight are a standard part of overall nutritional monitoring, and a healthcare professional oversees the appropriate energy intake.

Q: Can you eat and drink normally while receiving Smofkabiven?

A: Smofkabiven is officially indicated for use when a patient's normal oral or tube feeding (enteral) is impossible or insufficient. A healthcare professional determines if any oral intake is safe or appropriate while the patient is receiving the infusion.

Q: What is the purpose of the electrolytes included in Smofkabiven?

A: According to official product composition, electrolytes such as sodium and potassium are essential ingredients. They are included to help maintain the body's critical fluid and electrolyte balance. Official guidance indicates that existing disturbances in fluid and electrolyte balance should be addressed before the infusion is initiated.

Q: Is Smofkabiven used in a hospital setting or can it be used at home?

A: Smofkabiven requires administration by a qualified healthcare professional, and is typically given in a hospital or clinic setting. The label notes that the effect on driving is not relevant, as the medicine is typically given at the hospital. The administration setting is ultimately determined by the prescribing healthcare team.

Q: Does Smofkabiven interact with antibiotics?

A: Regulatory documents note that certain antibiotics, such as Ceftriaxone, should not be administered simultaneously with calcium-containing solutions (like Smofkabiven) through the same IV line. This is due to the risk of precipitation, or clumping, of components in the IV line.

Q: Can Smofkabiven be used by patients with heart failure?

A: Official product information indicates that the product is contraindicated for use in patients with heart failure that is untreated or clinically unstable. Eligibility for use is determined by a healthcare professional based on a patient's current medical status.

Q: What does the acronym 'SMOF' stand for in the drug name?

A: The term SMOF is associated with the unique four-source lipid blend contained in the emulsion. The blend uses a specific combination of Soya oil, Medium-chain triglycerides, Olive oil, and Fish oil (SMOF) to provide a complex profile of essential fatty acids.

How to Store and Dispose of Smofkabiven?

Storage before Mixing:

• Store the unmixed, multi-chamber bag in its overpouch.
• Keep the product at a temperature below 25°C (77°F).
• Do not freeze Smofkabiven.

Storage after Mixing and Disposal:

• Once the bag's chambers are mixed (activated), the solution is intended for immediate use.
• If not used immediately, the mixed emulsion is stable for up to 36 hours when stored at 25°C (77°F).
• If additives are introduced, the admixture should be used immediately. If not, it can typically be stored for no longer than 24 hours in a refrigerator between 2°C and 8°C (36°F to 46°F).
• Any unused portion of the medicine must be discarded after the recommended storage time or infusion period has passed.
• Dispose of the product and any associated waste material in accordance with local regulatory requirements for medical waste.